• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dosing of Etelcalcetide and Cinacalcet for Secondary Hyperparathyroidism.

作者信息

Hai Mary T Thanh, Guettier Jean-Marc, Rosebraugh Curtis J

机构信息

Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

出版信息

JAMA. 2017 May 23;317(20):2132. doi: 10.1001/jama.2017.4743.

DOI:10.1001/jama.2017.4743
PMID:28535228
Abstract
摘要

相似文献

1
Dosing of Etelcalcetide and Cinacalcet for Secondary Hyperparathyroidism.依特卡肽和西那卡塞治疗继发性甲状旁腺功能亢进的给药方法
JAMA. 2017 May 23;317(20):2132. doi: 10.1001/jama.2017.4743.
2
Dosing of Etelcalcetide vs Cinacalcet for Secondary Hyperparathyroidism-Reply.依替卡肽与西那卡塞治疗继发性甲状旁腺功能亢进的剂量比较——回复
JAMA. 2017 May 23;317(20):2132-2133. doi: 10.1001/jama.2017.4746.
3
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.依特立钙对比西那卡塞对继发性甲状旁腺功能亢进行血液透析患者甲状旁腺激素的影响：一项随机临床试验。
JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468.
4
Etelcalcetide for the treatment of secondary hyperparathyroidism.依替卡肽用于治疗继发性甲状旁腺功能亢进。
Expert Opin Pharmacother. 2017 Apr;18(5):529-534. doi: 10.1080/14656566.2017.1303482. Epub 2017 Mar 15.
5
Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.依特卡肽：用于治疗依赖血液透析患者继发性甲状旁腺功能亢进的注射用拟钙剂
Drugs Today (Barc). 2017 Sep;53(9):489-500. doi: 10.1358/dot.2017.53.9.2711938.
6
Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.依替卡肽在血液透析患者继发性甲状旁腺功能亢进管理中的作用：当前数据及治疗地位综述
Drug Des Devel Ther. 2018 Jun 1;12:1589-1598. doi: 10.2147/DDDT.S134103. eCollection 2018.
7
Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients.西那卡塞用于血液透析患者的继发性甲状旁腺功能亢进症
N Engl J Med. 2004 Jul 8;351(2):188-9; author reply 188-9.
8
Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.两年的盐酸西那卡塞治疗可减小晚期继发性甲状旁腺功能亢进血液透析患者的甲状旁腺体积并降低血清甲状旁腺激素水平。
Ther Apher Dial. 2015 Aug;19(4):367-77. doi: 10.1111/1744-9987.12292. Epub 2015 Apr 7.
9
Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients.低剂量拟钙剂西那卡塞在控制血液透析患者中重度继发性甲状旁腺功能亢进方面的耐受性和疗效
Saudi J Kidney Dis Transpl. 2015 Nov;26(6):1135-41. doi: 10.4103/1319-2442.168583.
10
[Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].西那卡塞——一种用于治疗尿毒症、甲状旁腺癌或原发性甲状旁腺功能亢进患者继发性甲状旁腺功能亢进的新药
Ugeskr Laeger. 2006 Jan 3;168(1):29-32.

引用本文的文献

1
The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in chinese healthy subjects: a randomized, placebo-controlled, double-blind, single-dose and dose-escalation phase I trial.SHR6508在中国健康受试者中的药代动力学、药效学及耐受性：一项随机、安慰剂对照、双盲、单剂量及剂量递增的I期试验
Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec 16. doi: 10.1007/s00210-024-03705-4.
2
New Intravenous Calcimimetic Agents: New Options, New Problems. An Example on How Clinical, Economical and Ethical Considerations Affect Choice of Treatment.新型静脉钙敏感受体激动剂：新选择，新问题。一个关于临床、经济和伦理考虑如何影响治疗选择的例子。
Int J Environ Res Public Health. 2020 Feb 14;17(4):1238. doi: 10.3390/ijerph17041238.